Menu
Česky English Deutsch
+420 532 23 1111

Nádorová genomika - publikace

2016

Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, Kotaskova J, Kantorova B, Hlozkova M, Figulova J, Brychtova Y, Machalova M, Urik M, Doubek M, Kozubik A, Pospisilova S, Pavlova S, Bryja V. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.Br J Haematol. 2016 Sep 21. doi: 10.1111/bjh.14312. v tisku IF=4.942

Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, Radova L, Tom N, Trbusek M, Diviskova E, Francova HS, Navrkalova V, Doubek M, Brychtova Y, Mayer J, Pospisilova S. Single cell analysis revealed a coexistence  of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic  leukaemia patients. Br J Haematol. 2016 Jul 29. v tisku IF=4.942

Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P; European Research Initiative on CLL (ERIC). Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? Haematologica. 2016 Mar;101(3):263-5. 139246 IF=6.671

Kotašková J, Pavlová Š, Greif I, Stehlíková O, Plevová K, Janovská P,Brychtová Y, Doubek M, Pospíšilová Š, Bryja V. ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. Br J Haematol. 2016 Oct;175(2):339-342. IF=4.942

Plesingerova H, Librova Z, Plevova K, Libra A, Tichy B, Skuhrova Francova H, Vrbacky F, Smolej L, Mayer J, Bryja V, Doubek M, Pospisilova S. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. Leuk Lymphoma. 2017 Jan;58(1):70-79

Navrkalova V, Young E, Baliakas P, Radova L, Sutton LA, Plevova K, Mansouri L, Ljungström V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis  P, Touloumenidou T, Davi F, Langerak AW, Ghia P, Strefford JC, Oscier D, Mayer J, Stamatopoulos K, Pospisilova S, Rosenquist R, Trbusek M. ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. Haematologica. 2016 Sep;101(9):e369-73. IF=6.671

Janovská P., Poppová L., Plevová K., Plešingerová H., Behal M., Kaucká M., Ovesná P., Hložková M., Borský M., Stehlíková O., Brychtová Y., Doubek M., Máchalová M., Baskar S., Kozubík A., Pospíšilová Š., Pavlová Š., Bryja V.: Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clinical Cancer Research (2016); 22(2): 459-469. IF=8,738

Ljungstrom V., Cortese D., Young E., Pandzic T., Mansouri L., Plevová K., Ntoufa S., Baliakas P., Clifford R., Sutton LA., Blakemore S., Stavroyianni N., Agathangelidis A., Rossi D., Hoglund M., Kotašková J., Juliusson G., Belessi C., Chiorazzi N., Panagiotidis P., Langerak AW., Smedby KE., Oscier D., Gaidano G., Schuh A., Davi F., Pott C., Strefford JC., Trentin L., Pospíšilová Š., Ghia P., Stamatopoulos K., Sjoblom T., Rosenquist R.: Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood (2016); 127(8): 1007-1016. IF=11,841

Rawston AC., Fazi C., Agathangelidis A., Villamor N., Letestu R., Nomdedeu J., Palacio C., Stehlíková O., Kreuzer KA., Liptrot S., O´Brien D., de Tute RM., Marinov I., Hauwel M., Špaček M., Dobber J., Kater APOD., Gambell P., Soosapilla A., Lozanski G., Brachtl G., Lin K., Boysen J., Hanson C., Jorgensen JL., Stetler-Stevenson M., Yuan C., Broome HE., Rassenti L., Craig F., Delgado J., Moreno C., Bosch F., Egle A., Doubek M., Pospíšilová Š., Mulligan S., Westerman D., Sanders CM., Emerson R., Robins HS., Kirsch I., Shanafelt T., Pettitt A., Kipps TJ., Wierda WG., Cymbalista F., Hallek M., Hillmen P., Montserrat E., Ghia P.: A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study. Leukemia (2016); 30(4): 929-936. IF=12,104

Feenstra Milosevic J., Nivarthi H., Gisslinger H., Leroy E., Rumi E., Chahoua I., Bagienski K., Kubešová B., Pietra D., Gisslinger B., Milanesi Ch., Jager R., Chen D., Berg T., Schalling M., Schuster M., Bock Ch., Constantinescu S., Cazzola M., Kralovics R.: Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood (2016); 127(3): 325-332. IF=11,841

Kopparapu PK., Bhoi S., Mansouri L., Arabanian L., Plevová K., Pospíšilová Š., Wasik A., Croci GA., Sander B., Paulli M., Rosenquist R., Kanduri M.: Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. Epigenetics (2016); 11(5): 335-343. IF=4,774

Nivarthi H., Chen D., Cleary C., Kubešová B., Jager R., Bogner E., Marty C., Pecquet C., Vainchenker W., Constantinescu SN., Kralovics R.: Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia (2016); 30(8): 1759-1763. IF=12,104

Baliakas P., Puiggros A., Xochelli A., Sutton LA., Nguyen-Khac F., Gardiner A., Plevová K., Minga E., Hadzidimitriou A., Walewska R., McCarthy H., Ortega M., Collado R., González T., Granada I., Luno E., Kotašková J., Moysiadis T., Davis Z., Stavroyianni N., Anagnostopoulos A., Strefford J., Pospíšilová Š., Davi F., Athanasiadou A., Rosenquist R., Oscier D., Espinet B., Stamatopoulos K.: Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica (2016); 101(7): e299-e302. IF=6,671

Sutton LA., Young E., Baliakas P., Hadzidimitriou A., Moysiadis T., Plevová K., Rossi D., Kmínková J., Stalika E., Pedersen LB., Malčíková J., Agathangelidis A., David Z., Masouri L., Scarfó L., Boudjoghra M., Navarro A., Muggen A., Yan XJ., Nguyen-Khac F., Larrayoz M., Panagiotidis P., Chiorazzi N., Niemann CU., Belessi Ch., Campo E., Strefford JC., Langerak AW., Oscier D., Gaidano G., Pospíšilová Š., Davi F., Ghia P., Stamatopoulos K., Rosenquist R., ERIC: Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica (2016); 101(8): 959-967. IF=6,671

 

2015

Baliakas P., Hadzidimitriou A., Sutton LA., Minga E., Agathangelidis A., Nichelatti M., Tsanousa A., Scarfó L., Davis Z., Yan XJ., Shanafelt T., Plevová K., Sandberg Y., Vojdeman FJ., Boudjogra M., Tzenou T., Chatzouli M., Chu Ch., Veronese S., Gardiner A., Mansouri L., Smedby K., Pedersen LB., van Lom K., Giudicelli V., Skuhrová Francová H., Nguyen-Khac F., Panagiotidis P., Juliusson G., Angelis L., Anagnostopoulos A., Lefranc MP., Facco M., Trentin L., Catherwood M., Montillo M., Geisler Ch., Langerak A., Pospíšilová Š., Chiorazzi N., Oscier D., Jelinek D., Darzentas N., Belessi Ch., Davi F., Rosenquist R., Ghia P., Stamatopolos K.: Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. The Lancet Haematology (2015); 1(2): e74-e84. IF=?

Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R.: Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia(2015); 29:329-336. IF=10,431

Kantorova B., Malcikova J., Smardova J., Pavlova S., Trbusek M., Tom N., Plevova K., Tichy B., Truong S., Diviskova E., Kotaskova J., Oltova A., Patten N., Brychtova Y., Doubek M., Mayer J., Pospisilova S.: TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. Tumour Biology (2015); 36(5): 3371-3380. IF=3,611

Musilova K., Mraz M.: MicroRNAs in B cell lymphomas: How a complex biology gets more complex. Leukemia (2015); 29(5): 1004-1017. IF=10,431

Seda V, Mraz M.: B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. European Journal of Haematology (2015); 94(3): 193-205. IF=2,066

Malčíková J., Staňo Kozubík K., Tichý B., Kantorová B., Pavlová Š., Tom N., Radová L., Šmardová J., Pardy F., Doubek M., Brychtová Y., Mráz M., Plevová K., Divíšková E., Oltová A., Mayer J., Pospíšilová Š., Trbušek M.: Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia (2015); 29(4): 877-885. IF=10,431

Trizuljak J., Srovnal J., Plevová K., Brychtová Y., Semerád L., Bakešová D., Létalová E., Benedíková A., Mayer J., Hajdúch M., Pospíšilová Š., Doubek M.: Analysis of prognostic significance of merkel cell polyomavirus in Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia (2015); 15(7): 439-442. IF=2,020

Mansouri L., Sutton LA., Ljungstrom V., Bondza S., Arngarden L., Bhoi S., Larsson J., Cortese D., Kalushkova A., Plevová K., Young E., Gunnarsson R., Falk-Sorqvist E., Lonn P., Muggen A., Yan XJ., Sander B.,Enblad G., Smedby K., Juliusson G., Belessi Ch., Rung J., Chiorazzi N., Strefford J., Langerak A., Pospíšilová Š., Davi F., Hellstrom M., Jernberg-Wiklund H., Ghia P., Soderberg O., Stamatopoulos K., Nilsson M., Rosenquist R.: Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia. Journal of Experimental Medicine (2015); 212(6): 833-843. IF=13,912

Moreno C., Montillo M., Panayiotidis P., Dimou M., Bloor A., Dupuis J., Schuh A., Noris S., Geisler Ch., Hillmen P., Doubek M., Trněný M., Obrtlíková P., Laurenti L., Stilgenbauer S., Smolej L., Ghia P., Cymbalista F., Jaeger U., Stamatopoulos K., Stavroyianni N., Carrington P., Zouabi H., Leblond V., Gomez-Garcia J., Rubio M., Marasca R., Musuraca G., Rigacci L., Farina L., Paolini R., Pospíšilová Š., Kimby E., Bradley C., Montserrat E.: Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica (2015); 100(4): 511-516. IF=5,814

Doubek M., Brychtová Y., Panovská A., Šebejová L., Stehlíková O., Chovancová J., Malčíková J., Šmardová J., Plevová K., Volfová P., Trbušek M., Mráz M., Bakešová D., Trizuljak J., Hadrabová M., Obrtlíková P., Karban J., Smolej L., Oltová A., Jelínková E., Pospíšilová Š., Mayer J.: Ofatumumab added to dexamethasone in patients with relapsed or refractory chornic lymphocytic leukemia: results from a phase II study. American Journal of Hematology (2015); 90(5): 417-421. IF=3,798

Xochelli A., Sutton LA., Agathangelidis A., Stalika E., Karypidou M., Marantidou F., Lopez AN., Papadopoulos G., Šupíková J., Groenen P., Boudjogra M., Sundstrom Ch., Ponzoni M., Skuhrová Francová H., Anagnostopoulos A., Pospíšilová Š., Papadaki T., Tzovaras D., Ghia P., Pott Ch., Davi F., Campo E., Rosenquist R., Hadzidimitriou A., Belessi Ch., Stamatopoulos K.: Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. The American Journal of Pathology (2015); 18(6): 1740-1748. IF=4,591

Verner J., Trbušek M., Chovancová J., Jašková Z., Moulis M., Folber F., Halouzka R., Mayer J., Pospíšilová Š., Doubek M.: NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines. Leukemia and Lymphoma (2015); 56(11): 3198-3206. IF=2,891

Baliakas P., Agathangelidis A., Hadzidimitriou A., Sutton LA., Minga E., Tsanousa A., Scarfó L., Davis Z., Yan XJ., Shanafelt T., Plevová K., Sandberg Y., Vojdeman FJ., Boudjogra M., Tzenou T., Chatzouli M., Chu Ch., Veronese S., Gardiner A., Mansouri L., Smedby K., Pedersen LB., Moreno D., Van Lom K., Giudicelli V., Skuhrová Francová H., Nguyen-Khac F., Panagiotidis P., Juliusson G., Angelis L., Anagnostopoulos A., Lefranc MP., Facco M., Trentin L., Catherwood M., Montillo M., Geisler Ch., Langerak A., Pospíšilová Š., Chiorazzi N., Oscier D., Jelinek D., Darzentas N., Belessi Ch., Davi F., Ghia P., Rosenquist R., Stamatopoulos K.: Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood (2015); 125(5): 856-859. IF=10,452

Navrkalová V., Rašková Kafková L., Divoký K., Pospíšilová Š.: Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients. Haematologica (2015); 100(8): 994-996. IF=5,868

Baliakas P., Hadzidimitriou A., Agathangelidis A., Rossi D., Sutton LA., Kmínková J., Scarfo L., Pospíšilová Š., Gaidano G., Stamatopoulos K.: Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood (2015); 126(8): 1043-1044. IF=10,452

 

2014

Baliakas P., Iskas M., Gardiner A., Davis Z., Plevová K., Nguyen-Khac F., Malčíková J., Anagnostopoulos A., Glide S., Mould S., Štěpanovská K., Brejcha M., Belessi Ch., Davi F., Pospíšilová Š., Athanasiadou A., Stamatopoulos K., Oscier D.: Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. American Journal of Hematology (2014); 89(3): 249-255. IF=3,477

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T.: European Research Initiative on CLL (ERIC). MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica(2014); 99(8):1285-1291. IF=5,868

Janíková A., Marečková A., Baumeisterova A., Krejčí M., Šupíková J., Šálek D., Horký O., Tichý B., Hanke I., Pospíšilová Š., Moulis M., Mayer J.: Transmission of t(11,14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma. Leukemia and Lymphoma (2014); 55(8): 1935-1938. IF=2,605

Kminkova J., Mraz M., Zaprazna K., Navrkalova V., Tichy B., Plevova K., Malcikova J., Cerna K., Rausch T., Benes V., Brychtova Y., Doubek M., Mayer J., Pospisilova S.: Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. Carcinogenesis(2014); 35(5): 992-1002. IF=5,266

Malcikova J., Stalika E., Davis Z., Plevova K., Trbusek M., Mansouri L., Scarfò L., Baliakas P., Gardiner A., Sutton L.A., Francova H.S., Agathangelidis A., Anagnostopoulos A., Tracy I., Makris A., Smardova J., Ghia P., Belessi C., Gonzalez D., Rosenquist R., Oscier D., Pospisilova S., Stamatopoulos K.: The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. British Journal of Haematology (2014); 166(4):621-625. IF = 4,959

Malcikova J., Pavlova S., Kozubik K.S., Pospisilova S.: TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Human Mutation (2014);35(6):663-671. IF=5,122

Mraz M., Chen L., Rassenti L.Z., Ghia E.M., Li H., Jepsen K., Smith E.N., Messer K., Frazer K.A., Kipps T.J.: miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood (2014); 124(1):84-95. IF = 9,775

Plevová K., Skuhrová Francová H., Burčková K., Brychtová Y., Doubek M., Pavlová Š., Malčíková J., Mayer J., Tichý B., Pospíšilová Š.: Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. Haematologica 2014; 99(2): 329-338. IF=5,868

Sebejova L, Borsky M, Jaskova Z, Potesil D, Navrkalova V, Malcikova J, Sramek M, Doubek M, Loja T, Pospisilova S, Mayer J, Trbusek M.: Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Experimental Hematology 2014;42(10): 867-874.e1. IF=2,806

Te RaaG.D., Malčiková J., Mraz M., Trbusek M., Le Garff-Tavernier M., Merle-Béral H., Greil R., Merkel O., Pospíšilová S., Lin K., Pettitt A.R., Stankovic T., van Oers M.H., Eldering E., Stilgenbauer S., Zenz T., Kater A.P., European Research Initiative on CLL (ERIC). Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. British Journal of Haematology (2014); 167(4):565-569. IF=4,959

Brejcha M, Stoklasová M, Brychtová Y, Panovská A, Štěpanovská K, Vaňková G, Plevová K, Oltová A, Horká K, Pospíšilová Š, Mayer J, Doubek M.: Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis. Leukemia Research (2014);38(2):170-175. IF=2,692

 

2013

Khare V., Lyakhovich A., Dammann K., Lang M., Borgmann M., Tichý B., Pospíšilová Š., Luciani G., Campregher Ch., Evstatiev R., Pflueger M., Hundsberger H., Gasche Ch.: Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochemical Pharmacology (2013); 85(2): 234-244. IF=4,529

Kaucká M., Plevová K., Pavlová Š., Janovská P., Mishra A., Verner J., Procházková J., Krejčí P., Kotašková J., Ovesná P., Tichý B., Brychtová Y., Doubek M., Kozubík A., Mayer J., Pospíšilová Š., Bryja V.: The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration. Cancer Research (2013); 73(5): 1491- 1501. IF=7,856

Mráz M., Staňo Kozubík K., Plevová K., Musilová K., Tichý B., Borský M., Kuglík P., Doubek M., Brychtová Y., Mayer J., Pospíšilová Š.: The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. Leukemia Research (2013); 37(7): 802-808. IF=2,923

Panovská A., Smolej L., Lysák D., Brychtová Y., Šimkovič M., Motyčková M., Vodárek P., Lindtnerová M., Trbušek M., Malčíková J., Pospíšilová Š., Mayer J., Doubek M.: The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide and rituximab. European Journal of Haematology (2013); 90(6): 479-485. IF=2,548

Krejčí M., Doubek M., Brychtová Y., Stehlíková O., Chovancová J., Tichý B., Skuhrová Francová H., Navrátil M., Tomíška M., Horký O., Pospíšilová Š., Mayer J.: Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia. Annals of Hematology (2013); 92(2):249-254. IF=2,615

Navrkalová V., Šebejová L., Zemanová J., Kmínková J., Kubešová B., Malčíková J., Mráz M., Šmardová J., Pavlová Š., Doubek M., Brychtová Y., Potěšil D., Neméthová V., Mayer J., Pospíšilová Š., Trbušek M.: ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. Haematologica (2013); 98(7): 1124-1131. IF=5,935

Te Raa D., Malčíková J., Pospíšilová Š., Trbušek M., Mráz M., Le Graff-Tavernier M., Merle-Béral H., Lin K., Pettitt A., Merkel O., Stankovic T., van Oers M., Eldering E., Stilgenbauer S., Zenz T., Kater A.: Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leukemia and Lymphoma (2013); 54(8): 1849-1853. IF=2,301

Navrkalová V., Šebejová L., Zemanová J., Jašková Z., Trbušek M.: The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene aktivity after fludarabine treatment in chronic lymphocytic leukemia cells. Leukemia and Lymphoma (2013); 54(8): 1840-1843. IF=2,301

Krejčí M., Doubek M., Dušek J., Brychtová Y., Ráčil Z., Navrátil M, Tomíška M., Horký O., Pospíšilová Š., Mayer J.: Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeoloid leukemia. Annals of Hematology (2013); 92(10): 1397-1403. IF=2,866

Strefford JC., Sutton LA., Baliakas P., Agathangelidis A., Malčíková J., Plevová K., Scarfo L., Davis Z., Stalika E., Cortese D., Cahill N., Pedersen LB., di Celle PF., Tzenou T., Geisler C., Panagiotidis P., Langerak AW., Chiorazzi N., Pospíšilová Š., Oscier D., Davi F., Belessi C., Mansouri L., Ghia P., Stamatopoulos K., Rosenquist R.: Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chornic lymphocytic leukemia: the case of SF3B1 and subset 2. Leukemia (2013); 27(11): 2196-2199. IF=10,164

Mráz M., Doubek M., Mayer J.: Inhibice signalizace B buněčným receptorem: první cílená léčba u chronické lymfocytární leukemie a dalších B buněčných lymfomů. Klinická Onkologie (2013); 26(3): 179-185.

Smolej L., Doubek M., Špaček M., Urbanová R., Obrtlíková P., Schwarz J., Lysák D., Pospíšilová Š., Jarošová M., Peková S., Kozák T.: Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL). Transfuze a hematologie dnes (2013); 19(2): 27-32.

Brejcha M., Stoklasová M., Brychtová Y., Panovská A., Štěpanovská K., Vaňková G., Plevová K., Oltová A., Horká K., Pospíšilová Š., Mayer J., Doubek M.: Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: A prospective analysis. Leukemia Research (2013); 38(2): 170-175. IF=2,587

Malčíková J., Rázga F., Jurček T., Dvořáková D., Žáčková D., Tošková M., Šebejová L., Šmardová J., Oltová A., Vaňková G., Juračková L., Trbušek M., Pospíšilová Š., Mayer J., Ráčil Z.: The BCR-ABL1 T315I mutation and additional genomic abbrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. Leukemia and Lymphoma (2013); 54(9): 2083-2087. IF= 2,301.

 

2012

Kostareli E., Gounari M., Janus A, Murray F., Brochet X., Giudicelli V., Pospíšilová Š., Oscier D., Foroni L., di Celle PF., Tichý B., Pedersen LB., Jurlander J., Ponzoni M., Kouvatsi A., Anagnostopoulos A., Thompson K., Darzentas N., Lefranc M-P., Belessi C., Rosenquist R., Davi F., Ghia P., Stamatopoulos K.: Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGVH4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia (2012); 26: 1127-1131. IF=10,164

Mráz M., Doležalová D., Plevová K., Staňo Kozubík K., Mayerová V., Černá K., Musilová K., Tichý B., Pavlová Š., Borský M., Verner J., Doubek M., Brychtová Y., Trbušek M., Hampl A., Mayer J., Pospíšilová Š.: MicroRNA-650 expression is influenced by imunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood (2012); 119(9): 2110-2113. IF=9,06

Doubek M., Trbušek M., Malčíková J., Brychtová Y., Šmardová J., Lochmanová J., Panovská A., Skuhrová Francová H., Mráz M., Tichý B., Šebejová L., Navrkalová V., Plevová K., Kuglík P., Mayer J., Pospíšilová Š.: Specific p53 mutations do not impact results of alemtuzumab therapy  among patients with chronic lymphocytic leukemia. Leukemia and Lymphoma (2012); 53(9): 1817-1819. IF=2,301

Verner J., Kabáthová J., Tomancová A., Pavlová Š., Tichý B., Mráz M., Brychtová Y., Krejčí M., Zdráhal Z., Trbušek M., Volejníková J., Sedláček P., Doubek M., Mayer J., Pospíšilová Š.: Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation. Experimental Hematology (2012); 40(11): 899-905. IF=2,907          

Lochmanová G., Jedličková L., Potěšil D., Tomancová A., Verner J., Pospíšilová Š., Doubek M., Mayer J., Zdráhal Z.: Potential biomarkers for early detection of acute graft-versus-host disease. Proteomics – Clinical Applications (2012); 6(7-8): 351-363. IF=2,925

Pospíšilová Š., Gonzalez D., Malčíková J., Trbušek M., Rossi D., Kater AP., Cymbalista F., Eichhorst B., Hallek M., Dohner H., Hillmen P., van Oers M., Gribben J., Ghia P., Montserrat E., Stilgenbauer S., Zenz T, ERIC.: ERIC reccommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012); 26(7): 1458-1461. IF=10,164

Agathangelidis A., Darzentas N., Hadzidimitriou A., Brochet X., Murray F., Yan XJ., Davis Z., van Gastel-Mol E., Tresoldi C., Chu Ch., Cahill N., Giudicelli V., Tichý B., Pedersen LB., Foroni L., Bonello L., Janus A., Smedby K., Anagnostopoulos A., Merle-Beral H., Laoutaris N., Juliusson G., di Celle PF., Pospíšilová Š., Jurlander J., Geisler Ch., Tsaftaris A., Lefranc MP., Langerak A., Oscier DG., Chiorazzi N., Belessi Ch., Davi F., Rosenquist R., Ghia P., Stamatopoulos K.: Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood (2012); 119(19): 4467-4475. IF=9,06

Mráz M., Trbušek M., Doležalová D., Malčíková J., Šupíková J., Staňo-Kozubík K., Kantorová B., Mayer J., Pospíšilová Š.: Identifikace patogeneticky významných mutací u chronické lymfocytární leukemie pomocí „sekvenování nové generace“.  Transfuze a Hematologie Dnes (2012); 18(2): 72-75.

Janíková A., Marečková A., Dvořáková D., Bortlíček Z., Tichý B., Navrátil M., Král Z., Pospíšilová Š., Mayer J.: A real-time (PCR) for a real life...? Quantitative evaluaton of BCL2/IGH in follicular lymphoma and its implications for clinical practice. Experimental Hematology (2012); 40(7): 528-539. IF=2,907

 

2011

Janíková A., Tichý B., Šupíková J., Staňo Kozubík K., Pospíšilová Š., Křen L., Vášová I., Šálek D., Mayer J.: Gene expression profiling in follicular lymphoma and its implication for clinical practice. Leuk. Lymphoma (2011), 52(1): 59-68. IF=2,397

Vargová K., Curik N., Burda P., Basová P., Kulvait V., Pospíšil V., Savvulidi F., Kokavec J., Necas E., Berková A., Obrtlíková P., Karban J., Mráz M., Pospíšilová Š., Mayer J., Trněný M., Zavadil J., Stopka T.: MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood (2011), 117(14): 3816-3825. IF=10,558

Mráz M., Zent C., Church A., Jelinek D., Wu X., Pospíšilová Š., Ansell S., Novak A., Kay N., Witzig T., Nowakowski G.: Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA4) with natalizumab can overcome this resistance. British Journal of Haematology (2011); 155(1): 53-64. IF=4,942

Trbušek M., Šmardová J., Malčíková J., Šebejová L., Dobeš P., Svitáková M., Vránová V., Mráz M., Skuhrová Francová H., Doubek M., Brychtová Y., Kuglík P., Pospíšilová Š., Mayer J.: Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor surfoval in chronic lymphocytic leukemia. Journal of Clinical Oncology (2011); 29(19): 2703-2708. IF=18,970

Kaucká M., Krejčí P., Plevová K., Pavlová Š., Procházková J., Janovská P., Valnohová J., Kozubík A., Pospíšilová Š., Bryja V.: Post-translational modifications regulate signalling by Ror I. Acta Physiologica (2011); 203(3): 351-362. IF=3,138

Doubek M., Mayer J., Obrtlíková P., Smolej L., Cmunt E., Schwarz J., Brejcha M., Kozmon P., Pospíšilová Š., Brychtová Y., Pospíšil Z., Trněný M.: Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. European Journal of Hematology (2011); 87(1): 130-137. IF=2,785

Trbušek M., Malčíková J., Mayer J.: Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia. Leukemia Research (2011); 35(7): 981-982. IF=2,555

Tvarůžková Z., Pavlová Š., Doubek M., Mayer J., Pospíšilová Š.: Lymfoproliferativní onemocnění u pacientů s autoimunitními a infekčními onemocněními: význam antigenní stimulace a zánětlivých procesů. Časopis lékařů českých (2011); 150(3): 161-168.

Létalová E., Doubek M., Folber F., Verner J., Mráz M., Pospíšilová Š., Mayer J.: Mikroprostředí kostní dřeně a jeho role v patogenezi leukemií. Transfuze a hematologie dnes (2011); 17(4): 171-176.

Informace o pohotovosti v Brně a Jihomoravském kraji